Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.53 |
| ▸ | FPR2 | P25090 | 4/20 | 0.53 |
| ▸ | FAAH | O00519 | 5/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880084 | 0.91 | GRM5 (0.54) | GRM5FPR2FAAHCNR2KMT2A | |
| SCHEMBL1578521 | 0.90 | GRM5 (0.53) | GRM5FPR2FAAHCNR2KMT2A | |
| SCHEMBL1578567 | 0.89 | GRM5 (0.52) | GRM5FPR2FAAHCNR2KMT2A | |
| SCHEMBL1578208 | 0.88 | FAAH (0.64) | GRM5FPR2FAAHCNR2KMT2A | |
| SCHEMBL1886593 | 0.87 | KMT2A (0.63) | GRM5FPR2FAAHCNR2KMT2A | |
| SCHEMBL1578988 | 0.84 | GRM5 (0.60) | GRM5FPR2FAAHCNR2KMT2A | |
| SCHEMBL1578562 | 0.83 | GRM5 (0.75) | GRM5FPR2FAAHCNR2KMT2A | |
| SCHEMBL3377291 | 0.81 | CNR2 (0.72) | FAAHCNR2KMT2AMEN1ATM | |
| SCHEMBL1579145 | 0.81 | GRM5 (0.58) | GRM5FPR2FAAHCNR2TSHR | |
| SCHEMBL3375838 | 0.81 | FAAH (0.56) | FAAHCNR2KMT2AMEN1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716284-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-05-06 | — | — | US | disclosed |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-07-18 | — | — | US | disclosed |
| US-8389519-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2013-03-05 | — | — | US | disclosed |
| US-20120270873-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-10-25 | — | — | US | disclosed |
| US-8198275-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-20110178086-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-07-21 | — | — | US | disclosed |
| US-20110178086-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-07-21 | — | — | US | disclosed |
| US-7947680-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S | 2011-05-24 | — | — | US | disclosed |
| US-7947680-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S | 2011-05-24 | — | — | US | disclosed |
| US-7947680-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S | 2011-05-24 | — | — | US | disclosed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270873-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | GRM5 3873/4885FPR2 3365/4885FAAH 2836/4885 |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | GRM5 3895/4885FPR2 3380/4885FAAH 2727/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | GRM5 4054/4885FPR2 3206/4885FAAH 2906/4885 |
| US-20110178086-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | GRM5 3873/4885FPR2 3365/4885FAAH 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.